The metabolic approach in patients with heart failure: Effects on left ventricle remodeling

Current Pharmaceutical Design

Volumn 15, Issue 8, 2009, Pages 850-856

  Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Glucagons like peptide 1; Metabolic modulation; Remodeling; Trimtazidine

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ADENOSINE DIPHOSPHATE; BIGUANIDE DERIVATIVE; CARNITINE PALMITOYLTRANSFERASE I; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE TRANSPORTER 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; PYRUVATE DEHYDROGENASE; ROSIGLITAZONE; SULFONYLUREA; TRIMETAZIDINE;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG RECEPTOR BINDING; FATTY ACID OXIDATION; FLUID RETENTION; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION;

GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HUMANS; RISK ASSESSMENT; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 65649105811     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582138     Document Type: Review

References (50)

1. Tang WH, Francis GS. Evolving concepts in left ventricular systolic and diastolic remodeling: Implications for therapy. Curr Cardiol Rep 2004; 6: 200-4.
2. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 2004; 110: 894-6.
3. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007; 356: 1140-51.
4. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-23.
5. Lopaschuk GD. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. Semin Cardiothorac Vasc Anesth 2006; 10: 228-30.
6. Knaapen P, Germans T, Knuuti J, Paulus WJ, Dijkmans PA, Allaart CP, et al. Myocardial energetics and efficiency: Current status of the noninvasive approach. Circulation 2007; 115: 918-27.
7. Herrmann G, Decherd GM. The chemical nature of heart failure. Ann Intern Med 1939; 12: 1233-44.
8. Sonnenblick EH, Skelton CL. Myocardial energetics: Basic principles and clinical implications. N Engl J Med 1971; 285: 668-75.
9. Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M, Vecoli C, et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2007; 293: H3270-8.
10. Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB. Insulin resistance in idiopathic dilated cardiomyopathy: A possible etiologic link. J Am Coll Cardiol 2004; 44: 78-81.
11. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, Shannon RP. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 2004; 61: 297-306.
12. Tang WH. Glycemic control and treatment patterns in diabetic patients with chronic heart failure. Curr Cardiol Rep 2007; 9: 242-7.
13. Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007; 49: 1696-704.
14. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-64.
15. Sambanis C, Tziomalos K, Kountana E, Kakavas N, Zografou I, Balaska A, et al. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol 2008; 45: 23-30.
16. Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: Results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008; 14: 445-52.
17. Frantz S, Hu K, Widder J, Bayer B, Witzel CC, Schmidt I, et al. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 2004; 141: 9-14.
18. Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I, et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 2002; 106: 2125-31.
19. Khoury VK, Haluska B, Prins J, Marwick TH. Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction. Heart 2003; 89: 61-5.
20. Diaz R, Goyal A, Mehta SR, Afzal R, Xavier D, Pais P, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007; 298: 2399-405.
21. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 2005; 293: 437-46.
22. Hermann HP, Pieske B, Schwarzmuller E, Keul J, Just H, Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: An open study. Lancet 1999; 353: 1321-3.
23. Lewis JF, DaCosta M, Wargowich T, Stacpoole P. Effects of dichloroacetate in patients with congestive heart failure. Clin Cardiol 1998; 21: 888-92.
24. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994; 23: 1617-24.
25. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144: 2242-52.
26. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-50.
27. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317: 1106-13.
28. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694-9.
29. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955-61.
30. Poornima I, Brown SB, Siva Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008; 1: 153-60.
31. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC, Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 2007; 292: R897-901.
32. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10: 1215-20.
33. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27: 942-8.
34. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005; 112: 3280-8.
35. Hermann HP, Arp J, Pieske B, Kogler H, Baron S, Janssen PM, et al. Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure. Eur J Heart Fail 2004; 6: 213-8.
36. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25: 1814-21.
37. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001; 22: 2164-70.
38. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990; 11: 207-12.
39. Di Napoli P, Di Giovanni P, Gaeta MA, D'Apolito G, Barsotti A. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J 2007; 154: 602, e1-5.
40. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8.
41. El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: A 24-month study. Am J Cardiovasc Drugs 2005; 5: 271-8.
42. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
43. Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: A post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol 2007; 50: 585-9.
44. Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, Hesse B, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008; 118: 1250-8.
45. Tang WH. Metabolic approach in heart failure: Rethinking how we translate from theory to clinical practice. J Am Coll Cardiol 2006; 48: 999-1000.
46. Tang WH, Shrestha K, Van Lente F, Troughton RW, Martin MG, Borowski AG, et al. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol 2008; 101: 370-3.
47. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ, et al. Moderate severity heart failure does not involve a down-regulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 2004; 287: H1538-43.
48. Mongiovi M, Pipitone S. Supraventricular tachycardia in fetus: How can we treat ? Curr Pharm Des 2008; 14(8): 736-42.
49. ten Hove M, Neubauer S. The application of NMR spectroscopy for the study of heart failure. Curr Pharm Des 2008; 14(18): 1787-97.
50. Vignati G, Annoni G. Characterization of supraventricular tachycardia in infants: Clinical and instrumental diagnosis. Curr Pharm Des 2008; 14(8): 729-35.